{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T10:10:34Z","timestamp":1794305434907,"version":"4.9.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is an increasing number of papers reporting the real world use of Nusinersen in different cohorts of SMA patients.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>The aim of this paper was to critically review the literature reporting real world data on motor function in type 2 and 3 patients treated with Nusinersen, subdividing the results according to SMA type, age and type of assessment and performing a meta-analysis of the available results. We also report the available data collected in untreated patients using the same measures. Of the 400 papers identified searching for Nusinersen and spinal muscular atrophy, 19 reported motor function in types 2 and 3: 13 in adults, 4 in children and 2 included both. Twelve papers reported untreated patients\u2019 data. All studies reported positive changes on at least one of the functional measures and at every time point while all-untreated cohorts showed negative changes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our review suggests that Nusinersen provides a favorable benefit in motor function across a wide range of SMA type 2 and 3 patients over a 10\u201314\u00a0month observation period. Although a direct comparison with studies reporting data from untreated patients cannot be made, the longitudinal changes in the treated cohorts (consistently positive) are divergent from those observed in the untreated cohorts (consistently negative). The difference could be observed both in the global cohorts and in smaller groups subdivided according to age, type or functional status.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-021-02065-z","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T12:13:35Z","timestamp":1634127215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":133,"title":["Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis"],"prefix":"10.1186","volume":"16","author":[{"given":"Giorgia","family":"Coratti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costanza","family":"Cutrona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Carmela","family":"Pera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bovis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Ponzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizia","family":"Chieppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Antonaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Sansone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Pane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9851-5365","authenticated-orcid":false,"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"2065_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/1750-1172-6-71","volume":"6","author":"A D'Amico","year":"2011","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6:71.","journal-title":"Orphanet J Rare Dis"},{"issue":"18","key":"2065_CR2","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"4","key":"2065_CR3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA, Connolly AM, Crawford TO, Darras BT, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284\u201393.","journal-title":"Lancet Neurol"},{"issue":"9","key":"2065_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/gt.2017.45","volume":"24","author":"M Scoto","year":"2017","unstructured":"Scoto M, Finkel RS, Mercuri E, Muntoni F. Therapeutic approaches for spinal muscular atrophy (SMA). Gene Ther. 2017;24(9):514\u20139.","journal-title":"Gene Ther"},{"issue":"10","key":"2065_CR5","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1056\/NEJMoa2009965","volume":"384","author":"G Baranello","year":"2021","unstructured":"Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, et al. Risdiplam in type 1 spinal muscular atrophy. N Engl J Med. 2021;384(10):915\u201323.","journal-title":"N Engl J Med"},{"issue":"18","key":"2065_CR6","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","volume":"377","author":"RS Finkel","year":"2017","unstructured":"Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723\u201332.","journal-title":"N Engl J Med"},{"issue":"7","key":"2065_CR7","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1710504","volume":"378","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, et al. Nusinersen versus Sham control in later-onset spinal muscular atrophy. N Engl J Med. 2018;378(7):625\u201335.","journal-title":"N Engl J Med"},{"issue":"3","key":"2065_CR8","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/ana.25533","volume":"86","author":"M Pane","year":"2019","unstructured":"Pane M, Coratti G, Sansone VA, Messina S, Bruno C, Catteruccia M, et al. Nusinersen in type 1 spinal muscular atrophy: twelve-month real-world data. Ann Neurol. 2019;86(3):443\u201351.","journal-title":"Ann Neurol"},{"issue":"14","key":"2065_CR9","doi-asserted-by":"publisher","first-page":"e1312","DOI":"10.1212\/WNL.0000000000006281","volume":"91","author":"K Aragon-Gawinska","year":"2018","unstructured":"Aragon-Gawinska K, Seferian AM, Daron A, Gargaun E, Vuillerot C, Cances C, et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study. Neurology. 2018;91(14):e1312\u20138.","journal-title":"Neurology"},{"issue":"1","key":"2065_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3233\/JND-190441","volume":"7","author":"A Pechmann","year":"2020","unstructured":"Pechmann A, Baumann M, Bernert G, Flotats-Bastardas M, Gruber-Sedlmayr U, von der Hagen M, et al. Treatment with Nusinersen\u2014challenges regarding the indication for children with SMA type 1. J Neuromuscul Dis. 2020;7(1):41\u20136.","journal-title":"J Neuromuscul Dis"},{"key":"2065_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.ejpn.2020.05.002","volume":"27","author":"L Szabo","year":"2020","unstructured":"Szabo L, Gergely A, Jakus R, Fogarasi A, Grosz Z, Molnar MJ, et al. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: real world data from Hungarian patients. Eur J Paediatr Neurol. 2020;27:37\u201342.","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"2065_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","volume":"15","author":"F Audic","year":"2020","unstructured":"Audic F, de la Banda MGG, Bernoux D, Ramirez-Garcia P, Durigneux J, Barnerias C, et al. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet J Rare Dis. 2020;15(1):148.","journal-title":"Orphanet J Rare Dis"},{"key":"2065_CR13","doi-asserted-by":"crossref","unstructured":"Gomez-Garcia de la Banda M, Amaddeo A, Khirani S, Pruvost S, Barnerias C, Dabaj I, et al. Assessment of respiratory muscles and motor function in children with SMA treated by Nusinersen. Pediatr Pulmonol. 2021;56(1):299\u2013306.","DOI":"10.1002\/ppul.25142"},{"key":"2065_CR14","first-page":"66","volume":"6","author":"G Coratti","year":"2021","unstructured":"Coratti G, Pane M, Lucibello S, Pera MC, Pasternak A, Montes J, et al. Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with Nusinersen. Neuromuscul Disorders. 2021;6:66.","journal-title":"Neuromuscul Disorders"},{"key":"2065_CR15","doi-asserted-by":"publisher","first-page":"175628642090780","DOI":"10.1177\/1756286420907803","volume":"13","author":"E Jochmann","year":"2020","unstructured":"Jochmann E, Steinbach R, Jochmann T, Chung HY, Rodiger A, Neumann R, et al. Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen. Ther Adv Neurol Disord. 2020;13:1756286420907803.","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"2065_CR16","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","volume":"91","author":"L Maggi","year":"2020","unstructured":"Maggi L, Bello L, Bonanno S, Govoni A, Caponnetto C, Passamano L, et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J Neurol Neurosurg Psychiatry. 2020;91(11):1166\u201374.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2065_CR17","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","volume":"19","author":"T Hagenacker","year":"2020","unstructured":"Hagenacker T, Wurster CD, Gunther R, Schreiber-Katz O, Osmanovic A, Petri S, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study. Lancet Neurol. 2020;19(4):317\u201325.","journal-title":"Lancet Neurol"},{"issue":"4","key":"2065_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3233\/JND-190416","volume":"6","author":"MC Walter","year":"2019","unstructured":"Walter MC, Wenninger S, Thiele S, Stauber J, Hiebeler M, Greckl E, et al. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA type 3\u2014a prospective observational study. J Neuromuscul Dis. 2019;6(4):453\u201365.","journal-title":"J Neuromuscul Dis"},{"key":"2065_CR19","first-page":"66","volume":"6","author":"T Kessler","year":"2020","unstructured":"Kessler T, Latzer P, Schmid D, Warnken U, Saffari A, Ziegler A, et al. Cerebrospinal fluid proteomic profiling in Nusinersen-treated patients with spinal muscular atrophy. J Neurochem. 2020;6:66.","journal-title":"J Neurochem"},{"key":"2065_CR20","first-page":"66","volume":"6","author":"CJJ Yeo","year":"2020","unstructured":"Yeo CJJ, Simeone SD, Townsend EL, Zhang RZ, Swoboda KJ. Prospective cohort study of Nusinersen treatment in adults with spinal muscular atrophy. J Neuromuscul Dis. 2020;6:66.","journal-title":"J Neuromuscul Dis"},{"issue":"8","key":"2065_CR21","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.1007\/s00415-020-09847-8","volume":"267","author":"A Osmanovic","year":"2020","unstructured":"Osmanovic A, Ranxha G, Kumpe M, Muschen L, Binz C, Wiehler F, et al. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy. J Neurol. 2020;267(8):2398\u2013407.","journal-title":"J Neurol"},{"key":"2065_CR22","first-page":"66","volume":"6","author":"B De Wel","year":"2020","unstructured":"De Wel B, Goosens V, Sobota A, Van Camp E, Geukens E, Van Kerschaver G, et al. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4. J Neurol. 2020;6:66.","journal-title":"J Neurol"},{"issue":"1","key":"2065_CR23","doi-asserted-by":"publisher","first-page":"11069","DOI":"10.1038\/s41598-020-68051-w","volume":"10","author":"K Kizina","year":"2020","unstructured":"Kizina K, Stolte B, Totzeck A, Bolz S, Schlag M, Ose C, et al. Fatigue in adults with spinal muscular atrophy under treatment with Nusinersen. Sci Rep. 2020;10(1):11069.","journal-title":"Sci Rep"},{"issue":"4","key":"2065_CR24","doi-asserted-by":"publisher","first-page":"e413","DOI":"10.1212\/WNL.0000000000009914","volume":"95","author":"O Moshe-Lilie","year":"2020","unstructured":"Moshe-Lilie O, Visser A, Chahin N, Ragole T, Dimitrova D, Karam C. Nusinersen in adult patients with spinal muscular atrophy: observations from a single center. Neurology. 2020;95(4):e413\u20136.","journal-title":"Neurology"},{"issue":"3","key":"2065_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.nmd.2020.12.006","volume":"31","author":"CG Konersman","year":"2021","unstructured":"Konersman CG, Ewing E, Yaszay B, Naheedy J, Murphy S, Skalsky A. Nusinersen treatment of older children and adults with spinal muscular atrophy. Neuromuscul Disord. 2021;31(3):183\u201393.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2065_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3233\/JND-200551","volume":"8","author":"RH Mendonca","year":"2021","unstructured":"Mendonca RH, Polido GJ, Matsui C, Silva AMS, Solla DJF, Reed UC, et al. Real-world data from nusinersen treatment for patients with later-onset spinal muscular atrophy: a single center experience. J Neuromuscul Dis. 2021;8(1):101\u20138.","journal-title":"J Neuromuscul Dis"},{"key":"2065_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1212\/CPJ.0000000000001033","volume":"6","author":"T Duong","year":"2021","unstructured":"Duong T, Wolford C, McDermott MP, Macpherson CE, Pasternak A, Glanzman AM, et al. Nusinersen treatment in adults with spinal muscular atrophy. Neurol Clin Pract. 2021;6:66. https:\/\/doi.org\/10.1212\/CPJ.0000000000001033.","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"2065_CR28","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/mus.26769","volume":"61","author":"A Veerapandiyan","year":"2020","unstructured":"Veerapandiyan A, Eichinger K, Guntrum D, Kwon J, Baker L, Collins E, et al. Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience. Muscle Nerve. 2020;61(2):222\u20136.","journal-title":"Muscle Nerve"},{"key":"2065_CR29","doi-asserted-by":"crossref","unstructured":"Pera MC CG, Bovis F, pane M, Pasternak A, Montes J, Sansone V, Dunaway Young S, Duong T, Messina S, Mizzoni I, D Amico A, Civitello M, Glanzman A, Bruno C, Salmin F, Morando S, de Sanctis R, Sframeli M, Antonaci L, Frongia AL, Rohwer A, Scoto M, de Vivo D, Darras B, Day J, Martens W, Patanella K, Bertini E, Muntoni F, Finkel R, Mercuri E. Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. Ann Clin Transl Neurol. 2021;in press.","DOI":"10.1002\/acn3.51411"},{"key":"2065_CR30","first-page":"66","volume":"6","author":"E Tiberi","year":"2020","unstructured":"Tiberi E, Costa S, Pane M, Priolo F, de Sanctis R, Romeo D, et al. Nusinersen in type 0 spinal muscular atrophy: should we treat? Ann Clin Transl Neurol. 2020;6:66.","journal-title":"Ann Clin Transl Neurol"},{"key":"2065_CR31","first-page":"39","volume":"10","author":"M Jedrzejowska","year":"2020","unstructured":"Jedrzejowska M. Advances in newborn screening and presymptomatic diagnosis of spinal muscular atrophy. Degener Neurol Neuromuscul Dis. 2020;10:39\u201347.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"9","key":"2065_CR32","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1212\/WNL.0000000000000741","volume":"83","author":"RS Finkel","year":"2014","unstructured":"Finkel RS, McDermott MP, Kaufmann P, Darras BT, Chung WK, Sproule DM, et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology. 2014;83(9):810\u20137.","journal-title":"Neurology"},{"issue":"1","key":"2065_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13023-020-01356-1","volume":"15","author":"E Mercuri","year":"2020","unstructured":"Mercuri E, Lucibello S, Perulli M, Coratti G, de Sanctis R, Pera MC, et al. Longitudinal natural history of type I spinal muscular atrophy: a critical review. Orphanet J Rare Dis. 2020;15(1):84.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2065_CR34","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883\u201391.","journal-title":"Ann Neurol"},{"issue":"11","key":"2065_CR35","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.nmd.2016.10.002","volume":"26","author":"R De Sanctis","year":"2016","unstructured":"De Sanctis R, Coratti G, Pasternak A, Montes J, Pane M, Mazzone ES, et al. Developmental milestones in type I spinal muscular atrophy. Neuromuscul Disord. 2016;26(11):754\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"2065_CR36","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.nmd.2017.09.015","volume":"28","author":"R De Sanctis","year":"2018","unstructured":"De Sanctis R, Pane M, Coratti G, Palermo C, Leone D, Pera MC, et al. Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy. Neuromuscul Disord. 2018;28(1):24\u20138.","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"2065_CR37","doi-asserted-by":"publisher","first-page":"e0199657","DOI":"10.1371\/journal.pone.0199657","volume":"13","author":"J Montes","year":"2018","unstructured":"Montes J, McDermott MP, Mirek E, Mazzone ES, Main M, Glanzman AM, et al. Ambulatory function in spinal muscular atrophy: age-related patterns of progression. PLoS ONE. 2018;13(6):e0199657.","journal-title":"PLoS ONE"},{"issue":"3","key":"2065_CR38","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/ene.13534","volume":"25","author":"RI Wadman","year":"2018","unstructured":"Wadman RI, Wijngaarde CA, Stam M, Bartels B, Otto LAM, Lemmink HH, et al. Muscle strength and motor function throughout life in a cross-sectional cohort of 180 patients with spinal muscular atrophy types 1c\u20134. Eur J Neurol. 2018;25(3):512\u20138.","journal-title":"Eur J Neurol"},{"issue":"5 Suppl","key":"2065_CR39","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.1097\/00002060-199509001-00009","volume":"74","author":"GT Carter","year":"1995","unstructured":"Carter GT, Abresch RT, Fowler WM Jr, Johnson ER, Kilmer DD, McDonald CM. Profiles of neuromuscular diseases. Spinal muscular atrophy. Am J Phys Med Rehabil. 1995;74(5 Suppl):S150-9.","journal-title":"Am J Phys Med Rehabil"},{"issue":"14","key":"2065_CR40","doi-asserted-by":"publisher","first-page":"e1988","DOI":"10.1212\/WNL.0000000000010540","volume":"95","author":"CA Wijngaarde","year":"2020","unstructured":"Wijngaarde CA, Stam M, Otto LAM, Bartels B, Asselman FL, van Eijk RPA, et al. Muscle strength and motor function in adolescents and adults with spinal muscular atrophy. Neurology. 2020;95(14):e1988\u201398.","journal-title":"Neurology"},{"issue":"4","key":"2065_CR41","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1002\/nbm.4473","volume":"34","author":"LAM Otto","year":"2021","unstructured":"Otto LAM, Froeling M, van Eijk RPA, Asselman FL, Wadman R, Cuppen I, et al. Quantification of disease progression in spinal muscular atrophy with muscle MRI-a pilot study. NMR Biomed. 2021;34(4):4473.","journal-title":"NMR Biomed"},{"issue":"9","key":"2065_CR42","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1007\/s00415-008-0929-0","volume":"255","author":"S Piepers","year":"2008","unstructured":"Piepers S, van den Berg LH, Brugman F, Scheffer H, Ruiterkamp-Versteeg M, van Engelen BG, et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. J Neurol. 2008;255(9):1400\u20134.","journal-title":"J Neurol"},{"issue":"12","key":"2065_CR43","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.nmd.2012.06.352","volume":"22","author":"U Werlauff","year":"2012","unstructured":"Werlauff U, Vissing J, Steffensen BF. Change in muscle strength over time in spinal muscular atrophy types II and III. A long-term follow-up study. Neuromuscul Disord. 2012;22(12):1069\u201374.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"2065_CR44","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acn3.51281","volume":"8","author":"M Annoussamy","year":"2021","unstructured":"Annoussamy M, Seferian AM, Daron A, Pereon Y, Cances C, Vuillerot C, et al. Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol. 2021;8(2):359\u201373.","journal-title":"Ann Clin Transl Neurol"},{"issue":"6","key":"2065_CR45","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/ana.25900","volume":"88","author":"G Coratti","year":"2020","unstructured":"Coratti G, Messina S, Lucibello S, Pera MC, Montes J, Pasternak A, et al. Clinical variability in spinal muscular atrophy type III. Ann Neurol. 2020;88(6):1109\u201317.","journal-title":"Ann Neurol"},{"issue":"9","key":"2065_CR46","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.nmd.2020.07.005","volume":"30","author":"G Coratti","year":"2020","unstructured":"Coratti G, Pera MC, Lucibello S, Montes J, Pasternak A, Mayhew A, et al. Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscul Disord. 2020;30(9):756\u201364.","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"2065_CR47","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358.","journal-title":"Stat Med"},{"issue":"4","key":"2065_CR48","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","volume":"66","author":"SY Kim","year":"2013","unstructured":"Kim SY, Park JE, Lee YJ, Seo HJ, Sheen SS, Hahn S, et al. Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity. J Clin Epidemiol. 2013;66(4):408\u201314.","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"2065_CR49","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1590\/0004-282x-anp-2020-0200","volume":"79","author":"RD Mendonca","year":"2021","unstructured":"Mendonca RD, Fernandes HD, Pinto RBS, Matsui C, Polido GJ, da Silva AMS, et al. Managing intrathecal administration of nusinersen in adolescents and adults with 5q-spinal muscular atrophy and previous spinal surgery. Arq Neuro-Psiquiat. 2021;79(2):127\u201332.","journal-title":"Arq Neuro-Psiquiat"},{"issue":"7","key":"2065_CR50","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.nmd.2015.04.009","volume":"25","author":"Finkel R, Bertini E, Muntoni F, Mercuri E, Group ESWS","year":"2015","unstructured":"Finkel R, Bertini E, Muntoni F, Mercuri E, Group ESWS. 209th ENMC International Workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7\u20139 November 2014, Heemskerk, The Netherlands. Neuromuscul Disord. 2015;25(7):593\u2013602.","journal-title":"Neuromuscul Disord"},{"issue":"7S","key":"2065_CR51","first-page":"7S40-7S4","volume":"27","author":"C Vuillerot","year":"2020","unstructured":"Vuillerot C. State of the art for motor function assessment tools in spinal muscular atrophy (SMA). Arch Pediatr. 2020;27(7S):7S40\u20134.","journal-title":"Arch Pediatr"},{"issue":"13","key":"2065_CR52","doi-asserted-by":"publisher","first-page":"e1241","DOI":"10.1212\/WNL.0000000000008166","volume":"93","author":"E Mercuri","year":"2019","unstructured":"Mercuri E, Lucibello S, Pera MC, Carnicella S, Coratti G, de Sanctis R, et al. Long-term progression in type II spinal muscular atrophy: a retrospective observational study. Neurology. 2019;93(13):e1241\u20137.","journal-title":"Neurology"},{"key":"2065_CR53","first-page":"66","volume":"6","author":"G Coratti","year":"2020","unstructured":"Coratti G, Pera MC, Lucibello S, Montes J, Pasternak A, Mayhew A, et al. Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscul Disord. 2020;6:66.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"2065_CR54","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Finkel R, Montes J, Mazzone ES, Sormani MP, Main M, et al. Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscul Disord. 2016;26(2):126\u201331.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"2065_CR55","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/mus.26419","volume":"59","author":"MC Pera","year":"2019","unstructured":"Pera MC, Coratti G, Mazzone ES, Montes J, Scoto M, De Sanctis R, et al. Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle Nerve. 2019;59(4):426\u201330.","journal-title":"Muscle Nerve"},{"issue":"10","key":"2065_CR56","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1212\/WNL.0000000000002445","volume":"86","author":"CA Chiriboga","year":"2016","unstructured":"Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, De Vivo DC, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86(10):890\u20137.","journal-title":"Neurology"},{"issue":"21","key":"2065_CR57","doi-asserted-by":"crossref","first-page":"e2492","DOI":"10.1212\/WNL.0000000000007527","volume":"92","author":"BT Darras","year":"2019","unstructured":"Darras BT, Chiriboga CA, Iannaccone ST, Swoboda KJ, Montes J, Mignon L, et al. Nusinersen in later-onset spinal muscular atrophy: long-term results from the phase 1\/2 studies. Neurology. 2019;92(21):e2492\u2013506.","journal-title":"Neurology"},{"issue":"5","key":"2065_CR58","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/mus.27187","volume":"63","author":"G Acsadi","year":"2021","unstructured":"Acsadi G, Crawford TO, Muller-Felber W, Shieh PB, Richardson R, Natarajan N, et al. Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study. Muscle Nerve. 2021;63(5):668\u201377.","journal-title":"Muscle Nerve"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02065-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-02065-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-02065-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T14:20:11Z","timestamp":1634134811000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-02065-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,13]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2065"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-02065-z","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,13]]},"assertion":[{"value":"18 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board (ethics committee) of Fondazione Policlinico Universitario Agostino Gemelli, as the coordinator center (N. 0030504\/18).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors GC, MCP, FB, VS, RF, MPa, EM, reports personal fees BIOGEN S.R.L., ROCHE, AVEXIS, NOVARTIS outside the submitted work; Authors CC, MPo, FC, LA have nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"430"}}